Avance Clinical Acquires U.S.-Based LumaBridge
January 7, 2026
Avance Clinical, an Australian full‑service CRO, has acquired LumaBridge, a U.S.-based oncology-focused clinical research organization. The deal expands Avance's U.S. footprint and establishes LumaBridge as the foundation of Avance's global Oncology Center of Excellence, strengthening oncology clinical trial capabilities from early‑phase through later‑phase programs.
- Buyers
- Avance Clinical
- Targets
- LumaBridge
- Industry
- Healthcare Services
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly & Company Acquires CrossBridge Bio
April 14, 2026
Biotechnology
Eli Lilly and Company has entered into a definitive agreement to acquire CrossBridge Bio, a Houston-based pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs). The deal provides for up to $300 million in total consideration, including upfront and milestone-based payments, to advance CrossBridge Bio’s TROP2-targeting TOP1i/ATRi ADC platform led by CBB-120.
-
Alcon to Acquire LumiThera
July 7, 2025
Medical Devices
Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.
-
Avance Clinical Acquires C3 Research Associates to Expand into North America
September 6, 2022
Healthcare Services
Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.
-
Summit Partners Makes Majority Growth Investment in LumaBridge
August 23, 2022
Healthcare Services
Summit Partners has made a majority growth equity investment in LumaBridge, an oncology-focused clinical research organization (CRO) headquartered in San Antonio, Texas. The capital will support LumaBridge’s expansion of clinical trial capabilities and enable the company to serve a larger number of emerging biopharma sponsors developing immuno-oncology therapies.
-
The Riverside Company Invests in Avance Clinical
November 9, 2021
Healthcare Services
The Riverside Company has invested in Avance Clinical, a leading Australian contract research organisation (CRO), to support the company's regional and international expansion. The investment will help Avance accelerate its clinical trials business — including vaccine and gene-technology studies — with a particular focus on growth in North America and Asia.
-
Global Healthcare Exchange (GHX) Acquires Lumere
January 13, 2020
Healthcare Services
Global Healthcare Exchange (GHX) acquired Chicago-based Lumere, an evidence-based data and analytics provider for healthcare supply chains and formulary management. The acquisition adds Lumere’s clinical data and machine-learning analytics to GHX’s cloud-based supply chain platform to improve device and drug intelligence and help health systems optimize cost and clinical outcomes. Financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.